Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | MPO | P05164 | 2/20 | 0.47 |
| ▸ | CREBBP | Q92793 | 4/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.46 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.44 |
| ▸ | PI4KA | P42356 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21492606 | 0.98 | L3MBTL1 (0.59) | L3MBTL1ADORA2AADORA1MPOCREBBP | |
| SCHEMBL31420829 | 0.86 | L3MBTL1 (0.57) | L3MBTL1ADORA2AADORA1MPOCREBBP | |
| SCHEMBL2413457 | 0.83 | L3MBTL1 (0.62) | L3MBTL1ADORA2AADORA1MPOCREBBP | |
| SCHEMBL21491759 | 0.82 | LMNA (0.66) | L3MBTL1CREBBPLOXL2GABRA1GABRR1 | |
| SCHEMBL9908393 | 0.81 | L3MBTL1 (0.61) | L3MBTL1ADORA2AADORA1MPOCREBBP | |
| SCHEMBL19948883 | 0.81 | L3MBTL1 (0.61) | L3MBTL1ADORA2AADORA1MPOCREBBP | |
| SCHEMBL1244019 | 0.81 | L3MBTL1 (0.61) | L3MBTL1ADORA2AADORA1MPOCREBBP | |
| Hydrochloric Acid SCHEMBL3763491 | 0.81 | L3MBTL1 (0.61) | L3MBTL1ADORA2AADORA1MPOCREBBP | |
| Hydrochloric Acid SCHEMBL21492580 | 0.81 | LMNA (0.69) | L3MBTL1CREBBPLOXL2GABRA1GABRR1 | |
| SCHEMBL31420605 | 0.80 | L3MBTL1 (0.59) | L3MBTL1ADORA2AADORA1MPOCREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-11572364-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-02-07 | — | — | US | disclosed |
| US-11059826-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-07-13 | — | — | US | disclosed |
| US-20190322673-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2019-10-24 | — | — | US | disclosed |
| EP-2970285-B1 | FUSED TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-2621926-B1 | PYRAZOLOPYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2017-08-30 | — | — | EP | disclosed |
| EP-2970285-A1 | FUSED TETRACYCLIC BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150150884-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2015-06-04 | — | — | US | disclosed |
| US-8980879-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8957077-B2 | Pyrazolopyrimidine PDE 10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8957077-B2 | Pyrazolopyrimidine PDE 10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-02-17 | — | — | US | disclosed |
| WO-2014164780-A1 | FUSED TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140256710-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2014-09-11 | — | — | US | disclosed |
| US-20130137707-A1 | PYRAZOLOPYRIMIDINE PDE 10 INHIBITORS | MERCK SHARP & DOHME LLC | 2013-05-30 | — | — | US | disclosed |
| US-20130137707-A1 | PYRAZOLOPYRIMIDINE PDE 10 INHIBITORS | MERCK SHARP & DOHME LLC | 2013-05-30 | — | — | US | disclosed |
| WO-2012044562-A2 | PYRAZOLOPYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137707-A1 | PYRAZOLOPYRIMIDINE PDE 10 INHIBITORS | PDE12, PDE5A, PDE4A | L3MBTL1 4059/4885ADORA2A 942/4885ADORA1 1825/4885 |
| US-11572364-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | L3MBTL1 4437/4885ADORA2A 1034/4885ADORA1 771/4885 |
| US-20150150884-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | L3MBTL1 1066/4885ADORA2A 983/4885ADORA1 406/4885 |
| US-20190322673-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | L3MBTL1 4437/4885ADORA2A 1034/4885ADORA1 771/4885 |
| US-11059826-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | L3MBTL1 4437/4885ADORA2A 1034/4885ADORA1 771/4885 |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | L3MBTL1 4437/4885ADORA2A 1034/4885ADORA1 771/4885 |
| US-20140256710-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | L3MBTL1 1066/4885ADORA2A 983/4885ADORA1 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.